Covid-19 roundup: Mod­er­na be­gins PhII/III vac­cine study in ado­les­cents; Pfiz­er and BioN­Tech's vac­cine gets an OK in Cana­da as the FDA meets to dis­cuss emer­gency use

Mod­er­na has launched a Phase II/III study of its Covid-19 vac­cine in ado­les­cents younger than 18 and old­er than 12, with the goal of read­ing out da­ta be­fore the 2021-2022 school year.

The tri­al, be­ing con­duct­ed with BAR­DA, will en­roll 3,000 par­tic­i­pants in the US and as­sess safe­ty and re­ac­to­genic­i­ty as the pri­ma­ry end­points. Mod­er­na CEO Stéphane Ban­cel said he ex­pects to read out da­ta in the spring of 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER